Osteopontin promotes tumor microenvironment remodeling and therapy resistance

被引:0
作者
Liu, Chao [1 ,2 ,3 ]
Xia, Shunjin [1 ,2 ,3 ]
Wang, Bo [1 ,2 ,3 ]
Li, Jiayong [1 ,2 ,3 ]
Wang, Xuyan [1 ,2 ,3 ]
Ren, Yu [2 ,3 ,4 ]
Zhou, Xuan [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Pathol, Tianjin 300060, Peoples R China
[2] Key Lab Basic & Translat Med Head & Neck Canc, Tianjin 300060, Peoples R China
[3] State Key Lab Druggabil Evaluat & Systemat Transl, Tianjin 300060, Peoples R China
[4] Tianjin Med Univ, Sch Basic Med Sci, Dept Genet, Tianjin 300070, Peoples R China
基金
中国国家自然科学基金;
关键词
ENDOTHELIAL GROWTH-FACTOR; DENDRITIC CELL-MIGRATION; BREAST-CANCER; PLASMA OSTEOPONTIN; GASTRIC-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER; SPLICE VARIANTS; EXPRESSION; METASTASIS;
D O I
10.1016/j.canlet.2025.217618
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteopontin (OPN) is a multifunctional secretory protein which can be expressed and secreted by a variety of tumor cells and immune cells. Tumor microenvironment remodeling provides favorable conditions for tumor progression, immune escape and therapy resistance. As a bridge molecule in crosstalk between tumor cells and tumor microenvironment, OPN can not only come from tumor cells to regulate the functions of various immune cells, promoting the formation of immunosuppressive environment, but also can be secreted by immune cells to act on tumor cells, leading to tumor progression, thus constructing a positive feedback regulatory network. Here, we summarize the molecular structure, source and receptor of OPN, and clarify the mechanism of OPN on tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, tumor progression and therapy resistance to comprehensively understand the great potential of OPN as a tumor biomarker and therapeutic target.
引用
收藏
页数:9
相关论文
共 140 条
  • [1] DNA damage response and resistance of cancer stem cells
    Abad, Etna
    Graifer, Dmitry
    Lyakhovich, Alex
    [J]. CANCER LETTERS, 2020, 474 : 106 - 117
  • [2] Agrawal D, 2002, J NATL CANCER I, V94, P513
  • [3] Osteopontin: a potentially important therapeutic target in cancer
    Ahmed, Mansoor
    Behera, Reeti
    Chakraborty, Goutam
    Jain, Shalini
    Kumar, Vinit
    Sharma, Priyanka
    Bulbule, Anuradha
    Kale, Smita
    Kumar, Santosh
    Mishra, Rosalin
    Raja, Remya
    Saraswati, Supriya
    Kaur, Rajinder
    Soundararajan, Gowrishankar
    Kumar, Dhiraj
    Thorat, Dhanashri
    Sanyal, Megha
    Ramdasi, Anuja
    Ghosh, Pompom
    Kundu, Gopal C.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (09) : 1113 - 1126
  • [4] Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis
    Allegrezza, Michael J.
    Rutkowski, Melanie R.
    Stephen, Tom L.
    Svoronos, Nikolaos
    Perales-Puchalt, Alfredo
    Nguyen, Jenny M.
    Payne, Kyle K.
    Singhal, Sunil
    Eruslanov, Evgeniy B.
    Tchou, Julia
    Conejo-Garcia, Jose R.
    [J]. CANCER RESEARCH, 2016, 76 (21) : 6253 - 6265
  • [5] Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
    Alva, Ajjai
    Slovin, Susan
    Daignault, Stephanie
    Carducci, Michael
    DiPaola, Robert
    Pienta, Ken
    Agus, David
    Cooney, Kathleen
    Chen, Alice
    Smith, David C.
    Hussain, Maha
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 749 - 757
  • [6] Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer
    Anborgh, Pieter H.
    Lee, Danny J.
    Stam, Pieter F.
    Tuck, Alan B.
    Chambers, Ann F.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (08) : 727 - 734
  • [7] Anborgh PH, 2015, AM J TRANSL RES, V7, P723
  • [8] Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
    Armstrong, Andrew J.
    Nixon, Andrew B.
    Carmack, Andrea
    Yang, Qian
    Eisen, Tim
    Stadler, Walter M.
    Jones, Robert J.
    Garcia, Jorge A.
    Vaishampayan, Ulka N.
    Picus, Joel
    Hawkins, Robert E.
    Hainsworth, John D.
    Kollmannsberger, Christian K.
    Logan, Theodore F.
    Puzanov, Igor
    Pickering, Lisa M.
    Ryan, Christopher W.
    Protheroe, Andrew
    George, Daniel J.
    Halabi, Susan
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3317 - 3328
  • [9] Osteopontin as a therapeutic target for cancer
    Bandopadhyay, Monalisa
    Bulbule, Anuradha
    Butti, Ramesh
    Chakraborty, Goutam
    Ghorpade, Priyanka
    Ghosh, Pompom
    Gorain, Mahadeo
    Kale, Smita
    Kumar, Dhiraj
    Kumar, Santosh
    Totakura, Kumar V. S.
    Roy, Gaurab
    Sharma, Priyanka
    Shetti, Dattatrya
    Soundararajan, Gowrishankar
    Thorat, Dhanashri
    Tomar, Deepti
    Nalukurthi, Radha
    Raja, Remya
    Mishra, Rosalin
    Yadav, Amit S.
    Kundu, Gopal C.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (08) : 883 - 895
  • [10] Suppression of the bacterial antigen-specific T cell response and the dendritic cell migration to the lymph nodes by osteopontin
    Begum, Mst. Dilara
    Umemura, Masayuki
    Kon, Shigeyuki
    Yahagi, Ayano
    Hamada, Satoru
    Oshiro, Kiyotetsu
    Gotoh, Kazuyo
    Nishizono, Akira
    Uede, Toshimitsu
    Matsuzaki, Goro
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 2007, 51 (01) : 135 - 147